Trials / Completed
CompletedNCT04746911
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
An Open Label, 4-Week, Phase 2, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Pediatric Subjects (Ages 2 to 5 Years Old) With Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Arcutis Biotherapeutics, Inc. · Industry
- Sex
- All
- Age
- 2 Years – 5 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 2 to 5 years old) with plaque psoriasis:
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ-151 cream 0.3% | ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2022-05-11
- Completion
- 2022-05-11
- First posted
- 2021-02-10
- Last updated
- 2023-03-10
Locations
18 sites across 3 countries: United States, Canada, Dominican Republic
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04746911. Inclusion in this directory is not an endorsement.